Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
4277 participants
INTERVENTIONAL
2019-09-26
2024-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Brief Acceptance and Commitment Therapy for HIV-infected At-risk Drinkers
NCT03974061
Engaging HIV Patients in Primary Care by Promoting Acceptance
NCT02004457
Adherence Intervention for HIV-infected Drug Users
NCT02907697
INcreasing Statin Prescribing in HIV Behavioral Economics REsearch
NCT03687060
Reducing Ethnic Health Disparities: Motivating HIV+ Latinos to Quit Smoking
NCT00503230
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Aim 1: To assess the impact of the implementation of an evidence-based, multilevel strategy to reduce cardiovascular vascular disease (CVD) among PLH.
Aim 2: To assess the process of implementation of these strategies using RE-AIM QuEST. Using both quantitative and qualitative methods, we evaluate the process of implementation by assessing Reach, \[Effectiveness addressed in Aim 1\], Adoption, Implementation and Maintenance whilst integrating Qualitative Evaluation for Systematic Translation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
CVD risk prior to the patient and clinician training
No interventions assigned to this group
Training
CVD risk after the patient and clinician training
ABCS training
Clinicians and patients will be given information regarding the ABCS (Aspirin, Blood Pressure control,Cholesterol control, and Smoking Cessation) and for reducing CVD risk among HIV patients.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ABCS training
Clinicians and patients will be given information regarding the ABCS (Aspirin, Blood Pressure control,Cholesterol control, and Smoking Cessation) and for reducing CVD risk among HIV patients.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Serve a cohort of at least 100 HIV patients
* Have an Electronic Health Record (EHR)
* Agree to collaborate on implementing feasible adaptations of intervention strategies
Patients:
* Patient of the site with a diagnosis of HIV
* Age 40-79 years
* ≥5% risk for CVD as calculated using the ASCVD Risk Estimator Plus
* Willing to participate
* No plans to leave the site in the next 12 months
* Proficient in either English or Spanish
* Own a cell phone with texting capabilities
Clinicians:
* Physicians, Physicians Assistants, or Nurse Practitioners who provide direct HIV care to patients
* Work at a participating site
* Willing to implement the project's intervention strategies
Exclusion Criteria
* Currently participating in another CVD trial
* Have experienced a prior cardiac or vascular event such as myocardial infarction (MI) or cerebrovascular accident (CVA)
* Have had a CVD procedure such as installation of a stent or angioplasty
* Have peripheral vascular disease, intermittent claudication or peripheral arterial disease
* Are pregnant
* Lacks capacity to consent
Clinicians:
• Planning to leave the site within the next 12 months
40 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clinical Directors Network
NETWORK
University of Texas
OTHER
National Heart, Lung, and Blood Institute (NHLBI)
NIH
University of Rochester
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kevin Fiscella
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kevin Fiscella, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
University of Rochester
Jonathan Tobin, PhD
Role: PRINCIPAL_INVESTIGATOR
Clinical Directors Network, Inc; Albert Einstein College of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Rochester
Rochester, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.